FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated